CTC
OPRX icon

Cetera Trust Company’s OptimizeRx OPRX Stock Holding History

Cetera Trust Company’s Portfolio OPRX Stock Details OPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,500
Closed -$18.2K – 420
2024
Q1 		$18.2K Sell
1,500
-3,900
-72% -$56.6K 0.01% 264
2023
Q4 		$77.3K Buy
+5,400
New +$51.8K 0.05% 213

Other funds holding OPRX

FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Samjo Management New York $231M AUM 13.04% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GIPM
G2 Investment Partners Management New York $406M AUM 164.47% 1-Year Est. Return

Cetera Trust Company's OPRX Position: Q2 2024 in Review

Cetera Trust Company sold out of OptimizeRx (OPRX) in Q2 2024, closing a stake of 1,500 shares — an estimated $18.2K sold.

Cetera Trust Company first reported a position in OPRX in Q4 2023 and held it in 2 quarters. The position peaked at $77.3K in Q4 2023. 92 funds tracked by Wall St. Rank hold OPRX as of Q2 2024.

  • Cetera Trust Company reported no remaining OptimizeRx position as of Q2 2024 after selling out during the quarter.
  • Cetera Trust Company sold 1,500 OptimizeRx shares in Q2 2024, an estimated $18.2K.
  • Cetera Trust Company first reported a position in OptimizeRx in Q4 2023 and held it in 2 quarters.
  • Cetera Trust Company's OptimizeRx position peaked at $77.3K in Q4 2023.
  • 92 funds tracked by Wall St. Rank held OptimizeRx as of Q2 2024.

Based on Cetera Trust Company's 13F filing for Q2 2024, filed 2 Aug 2024.